Événements
HBV-TAG Conférence 2021 (Sponsorship)
11-12 Juin 2021
Conférence virtuelle
ENYO Pharma a sponsorisé la conférence inaugurale virtuelle sur l’hépatite B – agents thérapeutiques de 2021.
www.hbv-tag.org
“The primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design,
Chronic Hepatitis B Drug Development Summit
5-6 Mai 2021
Pietro Scalfaro, notre directeur médical, présentera des résultats d’essais cliniques de notre composé principal Vonafexor au congrès “Chronic Hepatitis B Drug Development Summit” : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.
“This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection &
Immunotherapies & Innovations for Infectious Diseases Congress 2020
9-10 Décembre 2020
Edition Digitale
ENYO joindra la 4ème edition du congrès I4ID.
“The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach.”
AASLD 2020
13-16 Novembre 2020
Edition virtuelle
ENYO Pharma était connectée à l’édition virtuelle du AASLD meeting 2020.
Ce meeting confirme que vonafexor (EYP001, FXRAg) a un postionnement unique pour HBV et peut se différentier dans la NASH avec des phases 2 en bonne voie pour livrer des résultats au 1er semestre 2021.
Nous avons aussi présenté un poster décrivant une nouvelle petite molécule modulatrice des protéines mitochondriales NEET qui améliore l’inflammation et la fibrose dans le foie et les reins de souris NASH :
American Society of Nephrology – Kidney Week 2020
ENYO Pharma is present at the digital Kidney Week 2020 organized by the ASN with a poster. ASN has been honored to host the world’s premier meeting in nephrology for 50+ years, which has been “Reimagined” as a fully digital meeting.
“A novel small molecule modulating the mitochondrial NEET proteins improves inflammation and fibrosis in kidneys of NASH mice”
Dernière press release 